Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 106 Carcinoma, Non-Small-Cell Lung 34 Carcinoma, Renal Cell 23 Prostatic Neoplasms 17 Neoplasms 15 Brain Neoplasms 15 Neoplasm Metastasis 14 Lung Neoplasms 12 Breast Neoplasms 11 Uveal Melanoma 10 Pancreatic Neoplasms 10 Sarcoma 9 Small Cell Lung Carcinoma 7 Urinary Bladder Neoplasms 6 Squamous Cell Carcinoma of Head and Neck 6 Kidney Neoplasms 6 Diabetes Mellitus, Insulin-Dependent, 12 6 Carcinoma, Transitional Cell 6 Carcinoma, Hepatocellular 6 Skin Neoplasms 5 Ovarian Neoplasms 5 Histiocytoma, Malignant Fibrous 5 Colorectal Neoplasms 5 Uterine Cervical Neoplasms 4 Triple Negative Breast Neoplasms 4 Recurrence 4 Neuroendocrine Tumors 4 Mesothelioma 4 Glioblastoma 4 Colonic Neoplasms 4

Interventions

tremelimumab 1 regramostim 1 evolocumab 1 durvalumab 1 Radiotherapy 1 Radiation 1 Nivolumab 1 Ipilimumab 1 Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Lung Cancer Metastatic × Ipilimumab × Clear all

NCT05144529 2026-05-05

TOP2101

Duke University

Phase 2 Terminated

19 enrolled 16 charts

Lung Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡